Anthracycline-induced cardiorenal toxicity: from molecular mechanisms to clinical management - Takeaways - MDSpire

Anthracycline-induced cardiorenal toxicity: from molecular mechanisms to clinical management

  • By

  • Linke Jiao

  • Chao Yuan

  • Li Wang

  • Yating Zhao

  • Guoxia Zhang

  • Xinyu Yang

  • Yonghong Gao

  • Fan Yang

  • Xinye Li

  • Na An

  • Hongcai Shang

  • Yanwei Xing

  • May 12, 2026

  • 0 min

Share

  • 1

    Anthracyclines are essential in cancer treatment but are associated with significant cardiotoxicity and nephrotoxicity.

  • 2

    The interaction between cardiac and renal damage creates a cardiorenal vicious cycle, complicating anthracycline therapy.

  • 3

    Dexrazoxane is the only approved cardioprotective agent, but its effectiveness in protecting renal function is limited.

  • 4

    There are currently no standardized guidelines for preventing or managing anthracycline-induced cardiorenal toxicity.

  • 5

    A comprehensive understanding of the mechanisms and effective monitoring strategies is crucial for optimizing anthracycline therapy.

Original Source(s)

Anthracycline-induced cardiorenal toxicity: from molecular mechanisms to clinical management

  • by Linke Jiao, Chao Yuan, Li Wang, Yating Zhao, Guoxia Zhang, Xinyu Yang, Yonghong Gao, Fan Yang, Xinye Li, Na An, Hongcai Shang, Yanwei Xing

  • May 12, 2026

Related Content

Novel approaches for separating graft-versus-leukemia effects from graft-versus-host disease

Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report

Case Report: Synovial sarcoma with diffuse myxoid stroma and complete absence of epithelial differentiation in the extremity